This week in biotech was all about surveillance:
Two Toronto scientists studied over two million tweets to assess the social network’s value as a public health surveillance tool and came away impressed. Even though social networks open some completely new avenues to gathering data and interacting, for the most part they are just valuable tools for use in traditional processes according to a recent Deloitte report. and many Pharma companies remain reluctant to engage.
MaRS CEO Ilse Treurnicht, doing a bit of surveillance of her own on some publication surveillance data, noted that China is now second in publication of biomedical research articles globally, having recently surpassed Japan, the UK, Germany and Canada, among others. If you look at how often China’s scientists (as a whole) are cited by other scientists (a proxy for qualify or value), science in China still has a long way to go, though they have improved rapidly in “quality” as well.